Adherence has been shown to decrease over the first 5 years of treatment

Partridge, A. H. et al J Clin Oncol. 21:602-606 2003.

In the extended setting (5 - 7.5 years), non-compliance approaches 20%4

Fontein DBY. EJSO. 2012;38:110-117.

Reasons for Discontinuation5

In this study, side effects were the greatest reason for discontinuation

Current guidelines recognize the role of side effects in noncomplicance:

“Compliance to, and persistence with, adjuvant endocrine therapy for breast cancer is a clinical challenge...contribute to nonadherence….”

ASCO 2014 as published inJournal of Clinical Oncology

“Compliance to, and persistence with, adjuvant endocrine therapy for breast cancer is a clinical challenge. Patient adverse effects, personal health preferences, and out-of-pocket costs all contribute to nonadherence….”

–ASCO guidelines, J Clin Oncol, 20147

“Predictors of poor adherence to medication include the presence of side effects associated with the medication...”

NCCN Guidelines®, 2014

“Predictors of poor adherence to medication include the presence of side effects associated with the medication, and incomplete understanding by the patient of the benefits associated with regular administration of the medication.”

–NCCN Guideline®, 20146

“Helping patients understand the rationale for therapy, and the likely adverse effects, is likely to enhance treatment compliance and persistence.”

ASCO 2014 as published inJournal of Clinical Oncology

“Addressing patient beliefs about the benefits and risks of medications is warranted in patient-provider interactions about the use of adjuvant endocrine therapy. Helping patients understand the rationale for therapy, and the likely adverse effects, is likely to enhance treatment compliance and persistence.”

–ASCO guidelines, J Clin Oncol, 20147

Non-adherence impacts patient outcomes6

[BCI Predictive] biomarker should allow many women to avoid unnecessary treatment and for the focus to center on those in most need of therapy. This, in turn, could improve compliance with medication and further improve outcomes.

– Sgroi, et al. BCI-MA.17 study, J Natl Cancer Inst., 20137

References
  1. Partridge, A. H. et al J Clin Oncol. 21:602-606 2003.
  2. Murphy CC, et al. Breast Cancer Res Treat. 2012;134:459-4.
  3. Sheppard VB, et al. J Clin Oncol. 2014.
  4. Fontein DBY. EJSO. 2012;38:110-117.
  5. Friese CR et al. Breast Can Res Treat. 2013; 138(3)931-39.
  6. Hershman et al. Breast Can Res Treat. 2011;126(2):529-537.
  7. Burstein HJ, et al. J Clin Oncol. 2014;32:2255-69.
Breast Cancer Index Intended Use and Limitations

The Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test is intended for use in patients diagnosed with estrogen receptor-positive (ER+), lymph node-negative (LN-) or lymph node positive (LN+; with 1-3 positive nodes) early-stage, invasive breast cancer, who are distant recurrence-free. BCI provides: 1) a quantitative assessment of the likelihood of both late (post-5 years) and overall (0-10 year) distant recurrence following an initial 5 years of endocrine therapy (LN- patients) or 5 years of endocrine therapy plus adjuvant chemotherapy (LN+ patients), and 2) prediction of likelihood of benefit from extended (>5 year) endocrine therapy. BCI results are adjunctive to the ordering physician’s workup; treatment decisions require correlation with all other clinical findings.

This test was developed and its performance characteristics determined by Biotheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high complexity clinical laboratory testing.